A phase 1 trial of oncolytic HSV-1, g207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses

Molecular Therapy

Volumn 22, Issue 5, 2014, Pages 1048-1055

  Markert, James M ^a,b   Razdan, Shantanu N ^a   Kuo, Hui Chien ^c   Cantor, Alan ^c   Knoll, Anette ^d   Karrasch, Matthias ^e   Nabors, L Burt ^f   Markiewicz, Michael ^a   Agee, Bonita S ^a   Coleman, Jennifer M ^a   Lakeman, Alfred D ^b   Palmer, Cheryl A ^g   Parker, Jacqueline N ^a,b   Whitley, Richard J ^a,h   Weichselbaum, Ralph R ⁱ   Fiveash, John B ^j   Gillespie, G Yancey ^a,h  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d AK Statistics   (Germany)

^e JENA UNIVERSITY HOSPITAL   (Germany)

^f The University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j The University of Alabama at Birmingham   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ATAXIA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DYSPHASIA; FATIGUE; FEMALE; FEVER; GLIOBLASTOMA; HEMIPARESIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 1 G207; HUMAN; IMMUNE STATUS; LIQUORRHEA; MALE; MIDDLE AGED; NAUSEA; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; STEREOTACTIC TREATMENT; SURVIVAL RATE; SURVIVAL TIME; TIME TO TREATMENT; TONIC CLONIC SEIZURE; TREATMENT RESPONSE; TUMOR VOLUME; VIRUS SHEDDING; CLINICAL TRIAL; GENE THERAPY; GENETICS; GLIOMA; PATHOGENICITY; RADIOGRAPHY; VIROLOGY; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

ONCOLYTIC VIRUS;

ADULT; FEMALE; GENETIC THERAPY; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUS REPLICATION;

EID: 84899975310     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.22     Document Type: Article

References (31)

1. Dolecek, TA, Propp, JM, Stroup, NE and Kruchko, C (2012. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-oncology 14(suppl. 5: v1-49.
2. Hegi, ME, Diserens, AC, Gorlia, T, Hamou, MF, de Tribolet, N, Weller, M et al. (2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
3. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
4. Markert, JM, Liechty, PG, Wang, W, Gaston, S, Braz, E, Karrasch, M et al. (2009. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17: 199-207.
5. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD et al. (2000. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874.
6. Mineta, T, Rabkin, SD, Yazaki, T, Hunter, WD and Martuza, RL (1995. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938-943.
7. Advani, SJ, Sibley, GS, Song, PY, Hallahan, DE, Kataoka, Y, Roizman, B et al. (1998. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther 5: 160-165.
8. Bradley, JD, Kataoka, Y, Advani, S, Chung, SM, Arani, RB, Gillespie, GY et al. (1999. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res 5: 1517-1522.
9. Markert, JM, Gillespie, GY, Weichselbaum, RR, Roizman, B and Whitley, RJ (2000. Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 10: 17-30.
10. National Institutes of Health. Common Terminology Criteria for Adverse Events, Version 3.0. (2003.
11. Macdonald, DR, Cascino, TL, Schold, SC Jr and Cairncross, JG (1990. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280.
12. Markert, JM, Malick, A, Coen, DM and Martuza, RL (1993. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 32: 597-603.
13. Mineta, T, Markert, JM, Takamiya, Y, Coen, DM, Rabkin, SD and Martuza, RL (1994. CNS tumor therapy by attenuated herpes simplex viruses. Gene Ther 1(suppl. 1: S78.
14. Cobbs, C and Markert, JM (1999. Gene therapy of glioma: a review. Perspect Neurol Surg 10: 1-20.
15. Advani, SJ, Mezhir, JJ, Roizman, B and Weichselbaum, RR (2006. ReVOLT: radiationenhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 66: 637-646.
16. Adusumilli, PS, Stiles, BM, Chan, MK, Chou, TC, Wong, RJ, Rusch, VW et al. (2005. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann Thorac Surg 80: 409-16; discussion 416.
17. Jorgensen, TJ, Katz, S, Wittmack, EK, Varghese, S, Todo, T, Rabkin, SD et al. (2001. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 3: 451-456.
18. Stanziale, SF, Petrowsky, H, Joe, JK, Roberts, GD, Zager, JS, Gusani, NJ et al. (2002. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery 132: 353-359.
19. Kim, SH, Wong, RJ, Kooby, DA, Carew, JF, Adusumilli, PS, Patel, SG et al. (2005. Combination of mutated herpes simplex virus type 1 (G207 virus with radiation for the treatment of squamous cell carcinoma of the head and neck. Eur J Cancer 41: 313-322.
20. Bünzli, D, Wietlisbach, V, Barazzoni, F, Sahli, R and Meylan, PR (2004. Seroepidemiology of Herpes Simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 25-74 in 1992-93: a population-based study. BMC Infect Dis 4:10.
21. Hashido, M, Kawana, T, Matsunaga, Y and Inouye, S (1999. Changes in prevalence of herpes simplex virus type 1 and 2 antibodies from 1973 to 1993 in the rural districts of Japan. Microbiol Immunol 43: 177-180.
22. Rabenau, HF, Buxbaum, S, Preiser, W, Weber, B and Doerr, HW (2002. Seroprevalence of herpes simplex virus types 1 and type 2 in the Frankfurt am Main area, Germany. Med Microbiol Immunol 190: 153-160.
23. Chahlavi, A, Rabkin, S, Todo, T, Sundaresan, P and Martuza, R (1999. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 6: 1751-1758.
24. Todo, T, Feigenbaum, F, Rabkin, SD, Lakeman, F, Newsome, JT, Johnson, PA et al. (2000. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2: 588-595.
25. Choucair, AK, Levin, VA, Gutin, PH, Davis, RL, Silver, P, Edwards, MS et al. (1986. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 65: 654-658.
26. Pasquier, B, Pasquier, D, N'Golet, A, Panh, MH and Couderc, P (1980. Extraneural metastases of astrocytomas and glioblastomas: clinicopathological study of two cases and review of literature. Cancer 45: 112-125.
27. Agarwal, S, Manchanda, P, Vogelbaum, MA, Ohlfest, JR and Elmquist, WF (2013. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 41: 33-39.
28. Vogelbaum, MA, Jost, S, Aghi, MK, Heimberger, AB, Sampson, JH, Wen, PY et al. (2012. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO Working Group. Neurosurgery 70: 234-243.
29. Harrow, S, Papanastassiou, V, Harland, J, Mabbs, R, Petty, R, Fraser, M et al. (2004. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11: 1648-1658.
30. Papanastassiou, V, Rampling, R, Fraser, M, Petty, R, Hadley, D, Nicoll, J et al. (2002. The potential for efficacy of the modified (ICP 34.5(-herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 9: 398-406.
31. Rampling, R, Cruickshank, G, Papanastassiou, V, Nicoll, J, Hadley, D, Brennan, D et al. (2000. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716 in patients with recurrent malignant glioma. Gene Ther 7: 859-866.